Skip to Main Content
Volastra
Menu Button
About
Pipeline
Team
Join
News
Contact
News
Category:
Latest Updates
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
April 16, 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on...
Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline
March 7, 2023
Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will...
Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022
September 12, 2022
NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...
Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference
September 9, 2022
Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor...
Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day
May 12, 2022
NEW YORK, May 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...
Load More
